Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MHB036C in Advanced Solid Tumors
NCT06373406Phase 2Active, not recruiting
- Sponsor
- Minghui Pharmaceutical, Inc.
- Start
- May 2023
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MHB036C in solid tumor, sponsored by Minghui Pharmaceutical, Inc.. Started May 2023; status: active, not recruiting.
02
Drugs
MHB036C
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06373406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06373406.